Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Prices €1.2B Senior Notes Offering

NEW YORK – Thermo Fisher Scientific said on Monday that it has priced an offering of €1.2 billion ($1.33 billion) worth of euro-denominated senior notes.

The Waltham, Massachusetts-based company is offering €6 billion worth of senior notes with an interest rate of 1.75 percent per year and a due date of 2027, and €6 billion worth of senior notes with an interest rate of 2.375 percent per year and a due date of 2032.

The offering is expected to close on or about April 2, subject to customary closing conditions, and the notes will pay interest on an annual basis.

Thermo Fisher plans to use the proceeds of the offering to pay in part for the $11.5 billion acquisition of Qiagen, expected to close in the first half of 2021, including paying back Qiagen's debt. It also intends to use the proceeds for general corporate purposes, such as the acquisition of companies, the repayment and refinancing of debt, working capital and capital expenditures, and the repurchase of outstanding equity securities.

JP Morgan Securities, Morgan Stanley International, Merrill Lynch International, and Citigroup Global are joint book-running managers for the offering, as well as Credit Suisse Securities (Europe), MUFG Securities EMEA, and US Bankcorp Investments for the 2027 notes, and BNP Paribas, HSBC Bank, and SMBC Nikko Capital Markets for the 2032 notes.

The new offering comes a week after Thermo Fisher offered a total of $2.2 billion worth of senior notes, due in 2025 and 2030.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.